STAT3 and breast carcinoma: By covalently linking a STAT3 siRNA and a CTLA4-specific aptamer, this conjugate successfully inhibits STAT3 activity, promotes tumor-infiltrating CD8+ T cell functions, and retards tumor growth of PyMT breast cancer under HFD feeding [70].